Trial · NCT00362414
Beta-hCG + Erythropoietin in Acute Stroke
NCT00362414, Phase 2, Completed, University of California, Irvine; results first posted 2016-08-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Beta-hCG + Erythropoietin in Acute Stroke. Trials, record NCT00362414. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00362414
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Beta-hCG + Erythropoietin in Acute Stroke
- NCT number
- NCT00362414
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- Acute Stroke
- Interventions
- Dual Growth Factor
- First posted
- 2006-08-10
- Last updated
- 2016-08-29
- Results first posted
- 2016-08-29
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety | 3 mo | Safety through Day 90 was assessed through adverse event reporting, serial examinations, blood testing, and a leg vein Doppler at Day 42. Number of participants who experienced adverse events, had abnormality in serial examinations, blood testing, and a leg vein Doppler at Day 42. |
| Primary | Morbidity | 3 mo | attributable to experimental intervention |
| Primary | Mortality | 3 mo | attributable to experimental intervention |
| Secondary | Action Research Arm Test | 3 mo | The Action Research Arm Test is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3: Performs test normally 2: Completes test, but takes abnormally long or has great difficulty 1: Performs test partially 0: Can perform no part of test. Total scores range from 0-57 points, a higher score being better with 57 being considered "normal". |
| Secondary | Fugl-Meyer Arm Scale | 3 mo | Fugl-Meyer arm scale is a measurement scale of the upper body with three sections being Proximal, Wrist/Hand, and Coordination/Speed. The scores can range from 0-66 with a higher score being better. A score of 66 is considered "normal" with no impairments. |
| Secondary | Fugl-Meyer Leg Scale | 3 mo. | Measure of leg motor impairment with three subsections which are Proximal, Hip/Knee, and Speed/Coordination. The scale ranges from 0-34 with a higher score being better. A score of 34 is considered "normal". |
| Secondary | Boston Naming Test | 3 mo | Measure of aphasia or other language disturbance caused by stroke or other dementing disorders. It consists of 60 line drawings graded in difficulty in which patients are to name each picture. |
| Secondary | Line Cancellation Test | 3 mo | Measure of spatial neglect where patients must cross out lines placed in a random orientation. Missed lines may indicate areas of spatial neglect. |
| Secondary | NIH Stroke Scale | 3 mo | Measure of global impairment post stroke. It includes 11 items to examine levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. The scoring scale is between 0-42 where a higher score is indicative of a more severe stroke. |
| Secondary | Geriatric Depression Scale Short Form | 3 mo | Measure of depression done as a self-report. It is a series of 15 questions designed to be a screen for depression. The scores range from 0-15 with a higher score being more indicative of depression. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety | 3 mo | participants | NUMBER | |
| PRIMARY | Morbidity | 3 mo | participants | NUMBER | |
| PRIMARY | Mortality | 3 mo | participants | NUMBER | |
| SECONDARY | Action Research Arm Test | 3 mo | This number (9) is the total # subjects who could complete the test at all study time points; some subjects were unable to complete this test at one of the time points, especially the acute stroke assessment. | Units on a scale | MEDIAN |
| SECONDARY | Fugl-Meyer Arm Scale | 3 mo | Units on a scale | MEDIAN | |
| SECONDARY | Fugl-Meyer Leg Scale | 3 mo. | Units on a scale | MEDIAN | |
| SECONDARY | Boston Naming Test | 3 mo | Units on a scale | MEDIAN | |
| SECONDARY | Line Cancellation Test | 3 mo | ratio of canceled lines on each side | MEDIAN | |
| SECONDARY | NIH Stroke Scale | 3 mo | Units on a scale | MEDIAN | |
| SECONDARY | Geriatric Depression Scale Short Form | 3 mo | Units on a scale | MEDIAN |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety | Dual Growth Factor | 0 | participants | ||
| Morbidity | Dual Growth Factor | 0 | participants | ||
| Mortality | Two Growth Factors | 0 | participants | ||
| Action Research Arm Test | 2 Growth Factors | 23 | Full Range 0 to 57 | Units on a scale | |
| Fugl-Meyer Arm Scale | 2 Growth Factors | 32 | Full Range 2 to 65 | Units on a scale | |
| Fugl-Meyer Leg Scale | 2 Growth Factors | 20 | Full Range 3 to 34 | Units on a scale | |
| Boston Naming Test | 2 Growth Factors | 2 | Full Range 0 to 10 | Units on a scale | |
| Line Cancellation Test | 2 Growth Factors | 96 | Full Range 20 to 100 | ratio of canceled lines on each side | |
| NIH Stroke Scale | 2 Growth Factors | 10 | Full Range 6 to 19 | Units on a scale | |
| Geriatric Depression Scale Short Form | 2 Growth Factors | 5 | Full Range 0 to 12 | Units on a scale |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Beta-hCG + Erythropoietin | 15 | |
| Overall Study | COMPLETED | Beta-hCG + Erythropoietin | 12 | |
| Overall Study | NOT COMPLETED | Beta-hCG + Erythropoietin | 3 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Beta-hCG + Erythropoietin | 2 | 15 | 2 |
| serious | Deep Vein Thrombosis | Vascular disorders | Beta-hCG + Erythropoietin | 2 | 15 | 2 |
| serious | Cerebral embolism | Nervous system disorders | Beta-hCG + Erythropoietin | 1 | 15 | 2 |
| serious | Mediastinal sepsis | Infections and infestations | Beta-hCG + Erythropoietin | 1 | 15 | 1 |
| serious | Retroperitoneal hemorrhage | General disorders | Beta-hCG + Erythropoietin | 1 | 15 | 1 |
| serious | Cardiac arrest | Cardiac disorders | Beta-hCG + Erythropoietin | 1 | 15 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Beta-hCG + Erythropoietin | ||
| Total, other adverse events | Beta-hCG + Erythropoietin | 0 | 15 |
| Total, serious adverse events | Beta-hCG + Erythropoietin | 6 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00362414
GET https://conductscience.org/api/trials/v1/NCT00362414/registered